Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter, Cerus Enter $120 Mil. Platelet Market With EU Intercept Approval

This article was originally published in The Gray Sheet

Executive Summary

Baxter and Cerus plan to launch the first pathogen inactivation system for blood platelets by October, pending widespread blood bank validations and CE mark of a companion device

You may also be interested in...



Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data

Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete

Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data

Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete

Vitex, Baxter Target West Nile Virus With Red Blood Cell Screening Systems

West Nile Virus is one of the pathogens for which Baxter/Cerus and Vitex plan to market the red blood cell inactivation systems Intercept and Inactine, respectively

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel